Outcomes in NSCLC Patients with EGFR Co-Mutations Receiving Aumolertinib as First-Line Treatment: the Updated Results

被引：0
|
作者：
Fang, S. [1 ]
Xu, T. [1 ]
Liu, N. [1 ]
Wang, X. Y. [1 ]
Cheng, W. W. [1 ]
Fang, H. H. [1 ]
机构：
[1] Nanjing Chest Hosp, Affiliated Brain Hosp Nanjing Med Univ, Nanjing, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
aumolertinib; non-small-cell lung cancer; co-mutations;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP12.01-25
引用
收藏
页码：S650 / S650
页数：1
相关论文
共 50 条
  • [21] Study of First-Line Aumolertinib Plus Bevacizumab and Pemetrexed Treated NSCLC with EGFR Mutation and Brain Metastasis
    Fu, S.
    Liu, J.
    Fu, P.
    Li, H.
    Yang, X.
    Xie, C.
    Zhang, J.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S414 - S415
  • [22] Monitoring Plasma EGFR Mutations during First Line Treatment with EGFR TKIs in NSCLC Patients
    Mohorcic, Katja
    Kern, Izidor
    Janzic, Urska
    Hitij, Nina Turnsek
    Rot, Mitja
    Cufer, Tanja
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S388 - S389
  • [23] Treatment Patterns and Clinical Outcomes in Patients with EGFR-mutant NSCLC after Progression on First-Line Osimertinib
    Robinson, N. D.
    Zhan, P.
    Udelsman, B.
    Boffa, D. J.
    Goldberg, S. B.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S364 - S364
  • [24] Aumolertinib plus apatinib versus aumolertinib as first-line treatment in patients with EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer (NSCLC).
    Zhang, Fan
    Hu, Yi
    Han, Xiao
    Hu, ZhiSong
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [25] Prospective Study of Aumolertinib in NSCLC Patients with EGFR Sensitive Mutations Who Are Intolerant to Osimertinib Treatment
    Lu, S.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S468 - S468
  • [26] First-line treatment in NSCLC harboring EGFR common mutations: EGFR TKI in monotherapy or in combination with anti-VEGF?
    Passaro, Antonio
    Spitaleri, Gianluca
    de Marinis, Filippo
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (08) : 799 - 801
  • [27] Clinical Outcomes of Non-Small Cell Lung Cancer (NSCLC) Patients with ALK Co-Mutations (EGFR or KRAS) Receiving Tyrosine Kinase Inhibitors (TKI)
    Schmid, Sabine
    Gautschi, Oliver
    Rothschild, Sacha
    Mauti, Laetitia
    Mark, Michael
    Froesch, Patrizia
    Fruh, Martin
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1505 - S1505
  • [28] First-line osimertinib for patients with advanced NSCLC harboring EGFR mutations: A real-world study
    Ji, W.
    Jiang, D.
    Zhang, J.
    Zhang, H.
    Wang, Q.
    Cang, S.
    Li, X.
    Tan, J.
    Xiang, Y.
    Li, X.
    Liu, A.
    Lu, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S1693 - S1693
  • [29] GEFITINIB FOR THE FIRST-LINE TREATMENT OF NSCLC PATIENTS WITH EGFR MUTATIONS IN EXONS 19 OR 21: ANALYSIS OF 74 PATIENTS FROM CZECH REPUBLIC
    Skrickova, Jana
    Bortlicek, Zdenek
    Hejduk, Karel
    Pesek, Milos
    Kolek, Vitezslav
    Koubkova, Leona
    Tomiskova, Marcela
    Satankova, Monika
    Povolna, Zdenka
    Coupkova, Helena
    Havel, Libor
    Zemanova, Milada
    Sixtova, Dimka
    Salajka, Frantisek
    Cernovska, Marketa
    Hrnciarik, Michal
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S599 - S599
  • [30] Activity of afatinib in patients with NSCLC harboring novel uncommon EGFR mutations with or without co-mutations: a case report
    Christopoulos, Petros
    Herster, Franziska
    Hoffknecht, Petra
    Falk, Markus
    Tiemann, Markus
    Kopp, Hans-Georg
    Althoff, Andre
    Stammberger, Anja
    Laack, Eckart
    FRONTIERS IN ONCOLOGY, 2024, 14
12345